Literature DB >> 12091347

Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.

Tuna Mutis1, Els Blokland, Michel Kester, Ellen Schrama, Els Goulmy.   

Abstract

Successful stem cell transplantation (SCT) across HLA barriers can be performed with cord blood, megadoses of stem cells, or with nonmyeloablative conditioning strategies. Because the HLA-mismatched transplants are often T-cell depleted, leukemia relapse rates are high. Treatment of relapsed leukemia after HLA-mismatched SCT is difficult. A novel potential strategy to treat relapsed leukemia after HLA-mismatched SCT is the use of patients' mismatched HLA molecules as antigen-presenting molecules to generate hematopoietic system-specific cytotoxic T cells (CTLs) from the stem cell donor. Adoptive transfer of these hematopoietic system-specific CTLs that are restricted by nonself HLA molecules may eliminate leukemia without affecting the patient's nonhematopoietic cells or donor hematopoietic cells. We investigated the feasibility of this strategy using the hematopoietic system-specific minor histocompatibility antigen HA-1, which is known to induce HLA-A2-restricted CTLs. HLA-A2(-) peripheral blood mononuclear cells were stimulated with HLA-A2(+) T2 cells pulsed with synthetic HA-1 peptide or with dendritic cells transduced with the HA-1 cDNA. Tetrameric HLA-A2/HA-1 peptide complexes were used to monitor and enrich HA-1-specific CTLs. In the alloreactive cultures, HA-1-specific CTLs were enriched up to 7% by 3 rounds of antigen-specific stimulations and up to 87% by fluorescence-activated cell sorting of tetramer-positive T cells. The HA-1-specific CTLs showed specific lysis of the relevant target cells, including leukemic cells. Because the polyclonal CTL cultures also contained natural killer cells and allo-HLA-A2-specific CTLs, CTL clones were generated that showed the expected HA-1 specificity only. Thus, HA-1-specific CTLs restricted by nonself HLA-A2 molecules can be generated in an HLA-A2-mismatched setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091347     DOI: 10.1182/blood-2002-01-0024

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues.

Authors:  Corbett J A Reinbold; Subramaniam Malarkannan
Journal:  Mol Immunol       Date:  2007-11-05       Impact factor: 4.407

Review 2.  Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.

Authors:  Malcolm K Brenner; Fatma V Okur
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

3.  Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.

Authors:  Persis P Wadia; Marc Coram; Randall J Armstrong; Michael Mindrinos; Atul J Butte; David B Miklos
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

Review 4.  Prospects for immunotherapy of malignant disease.

Authors:  E C Morris; G M Bendle; H J Stauss
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 5.  Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Tuna Mutis
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 6.  Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.

Authors:  Conrad R Y Cruz; Catherine M Bollard
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 7.  New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.

Authors:  H Joachim Deeg
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

8.  Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.

Authors:  U Thiel; S Pirson; C Müller-Spahn; H Conrad; D H Busch; H Bernhard; S Burdach; G H S Richter
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

Review 9.  Identification of human tumor antigens recognized by T-cells and their use for immunotherapy.

Authors:  Yutaka Kawakami
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.319

10.  Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Renate Hagedoorn; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.